IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Gauldie & Braciak

Application No.: 09/742,893

Filed: 12/21/2000

Title: ACNE VACCINE

Group Art Unit: 1614



Gloup Art Ollit. 1

Attorney Docket No.: GDI-2

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

This is in response to a Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures under 37 CFR §1.821(e)(f)(g) and 37 C.F.R. §1.825(b)(d) Enclosed is a copy of said Notice and the following documents to complete the filing requirements of the above-captioned application.

- (X) Paper copy of Sequence Listing. Please insert the Sequence Listing after the Abstract, but before the figures of the above-captioned application.
- (X) Copy of Sequence Listing on diskette.
- (X) Sequence Listing Statement.
- (X) Petition and Fee for a One-Month Extension of Time.
- (X) Payment is by Credit Card. Form PTO-2038 is attached.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope with sufficient postage addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit: 10/16/2001

Typed Name: Timothy H. Van Dyke

Signature.


Respectfully submitted,

Timothy H. Van Dyke, Reg. No. 43218

Customer No: 29847

Date: 10/16/2001

Telephone No.: 407-228-0328





United States Patent and Trademark Office

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE

WASHINGTON, D.C. 20231 www.uspto.gov

APPLICATION NUMBER

FILING DATE

FIRST NAMED APPLICANT

ATTY. DOCKET NO./TITLE

09/742,892

Jack Gauldie

GDI-2

Timothy H. Van Dyke Bencen & Van Dyke, P.A., 1630 Hillcrest Street

Orlando, FL 32803

CONFIRMATION NO. 8232 CORRECTION COVER LETTER

OC000000006300262

Date Mailed: 07/16/2001

COVER LETTER FOR CORRECTION OF PREVIOUS NOTICE

The Notice mailed on 03/09/2001 was sent in error and is hereby withdrawn. A corrected Notice is enclosed. The time period for reply runs from the mail date of the corrected Notice. We apologize for any inconvenience this caused.

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



United States Patent and Trademark Office

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231 www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/742,892

Jack Gauldie

GDI-2

CONFIRMATION NO. 8232

FORMALITIES LETTER

OC000000006300280*

Timothy H. Van Dyke Bencen & Van Dyke, P.A., 1630 Hillcrest Street Orlando, FL 32803

Date Mailed: 07/16/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

1 agc 2 01 2

Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE

COPY OF PAPERS ORIGINALLY FILED